Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Wakelee, H. ELSEVIER SCIENCE INC. 2021: S773–S774

View details for Web of Science ID 000634855900139